New York State Teachers Retirement System Takes Position in Indivior PLC $INDV

New York State Teachers Retirement System purchased a new position in Indivior PLC (NASDAQ:INDV) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 85,251 shares of the company’s stock, valued at approximately $3,059,000.

Several other large investors have also recently made changes to their positions in INDV. Oaktree Capital Management LP boosted its position in shares of Indivior by 2,241.6% in the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after purchasing an additional 246,776,273 shares in the last quarter. Divisadero Street Capital Management LP lifted its holdings in shares of Indivior by 2,372.5% in the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after buying an additional 3,226,605 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Indivior by 57.9% in the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock valued at $196,403,000 after buying an additional 2,008,078 shares during the period. Goldentree Asset Management LP acquired a new position in shares of Indivior in the 3rd quarter valued at about $42,630,000. Finally, Newtyn Management LLC increased its stake in shares of Indivior by 61.1% in the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock valued at $101,262,000 after purchasing an additional 1,592,982 shares in the last quarter. 60.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on INDV shares. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday. Northland Securities set a $50.00 price target on Indivior in a research report on Tuesday, January 20th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Finally, HC Wainwright upped their price objective on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Indivior currently has a consensus rating of “Buy” and an average price target of $39.33.

Insider Buying and Selling

In other Indivior news, Director Stuart A. Kingsley bought 940 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average price of $31.86 per share, with a total value of $29,948.40. Following the completion of the acquisition, the director directly owned 5,582 shares of the company’s stock, valued at $177,842.52. This represents a 20.25% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.74% of the stock is owned by company insiders.

Indivior Trading Down 2.5%

Indivior stock opened at $39.60 on Friday. Indivior PLC has a twelve month low of $10.63 and a twelve month high of $41.00. The stock’s fifty day simple moving average is $32.24 and its 200-day simple moving average is $32.85. The firm has a market capitalization of $4.83 billion, a P/E ratio of 20.31 and a beta of 0.90.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The business had revenue of $317.00 million for the quarter. Sell-side analysts predict that Indivior PLC will post 3.35 earnings per share for the current year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.